Evidence map›Paper›PMID 35964203›Full record

SynthesisJournal of Parkinson's disease2022

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.

K Ray Chaudhuri, Angelo Antonini, Rajesh Pahwa, Per Odin, Nataliya Titova, Sandeep Thakkar, Sonya J Snedecor, Saket Hegde, Ali Alobaidi, Juan Carlos Parra and 3 more

Open access · hybridAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Observational
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 5 countries.

K Ray ChaudhuriParkinson Foundation Centre of Excellence, King's College Hospital and King's College, London, UK.
Angelo AntoniniParkinson and Movement Disorders Unit, Study Center for Neurodegeneration CESNE, Department of Neuroscience, University of Padova, Padova, Italy.
Rajesh PahwaUniversity of Kansas Medical Center, Kansas City, KS, USA.
Per OdinUniversity of Lund, Lund, Sweden.
Nataliya TitovaN.I. Pirogov Russian National Research Medical University, Moscow, Russia.
Sandeep ThakkarHoag Hospital Newport Beach, Newport Beach, CA, USA.
Sonya J SnedecorOPEN Health, Bethesda, MD, USA.
Saket HegdeOPEN Health, New York, NY, USA.
Ali AlobaidiAbbVie Inc., North Chicago, IL, USA.
Juan Carlos ParraAbbVie Inc., North Chicago, IL, USA.
Cindy ZadikoffAbbVie Inc., North Chicago, IL, USA.
Lars BergmannAbbVie Inc., North Chicago, IL, USA.
David G StandaertUniversity of Alabama at Birmingham, Birmingham, AL, USA.
AbbVie (United States) · USHoag Memorial Hospital Presbyterian · USKing's College London · GBLund University · SEOpen Health Systems Laboratory · USOpen Society Foundations · USPirogov Russian National Research Medical University · RUUniversity of Alabama at Birmingham · USUniversity of Kansas Medical Center · USUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn advanced Parkinson's disease (PD), dyskinesias and non-motor symptoms such as sleep dysfunction can significantly impair quality of life, and high-quality management is an unmet need.

objectiveTo analyze changes in dyskinesia and non-motor symptoms (including sleep) among studies with levodopa-carbidopa intestinal gel (LCIG) in patients with advanced PD.

methodsA comprehensive literature review identified relevant studies examining LCIG efficacy. Outcomes of interest were dyskinesia (UDysRS, UPDRS IV item 32), overall non-motor symptoms (NMSS), mentation/behavior/mood (UPDRS I), and sleep/daytime sleepiness (PDSS-2, ESS). The pooled mean (95% confidence interval) change from baseline per outcome was estimated for each 3-month interval with sufficient data (i.e., reported by≥3 studies) up to 24 months using a random-effects model.

resultsSeventeen open-label studies evaluating 1243 patients with advanced PD were included. All outcomes of interest with sufficient data for meta-analysis showed statistically significant improvement within 6 months of starting LCIG. There were statistically significant improvements in dyskinesia duration as measured by UPDRS IV item 32 at 6 months (-1.10 [-1.69, -0.51] h/day) and 12 months (-1.35 [-2.07, -0.62] h/day). There were statistically and clinically significant improvements in non-motor symptoms as measured by NMSS scores at 3 months (-28.71 [-40.26, -17.15] points). Significant reduction of NMSS burden was maintained through 24 months (-17.61 [-21.52, -13.70] points). UPDRS I scores significantly improved at 3 months (-0.39 [-0.55, -0.22] points). Clinically significant improvements in PDSS-2 and ESS scores were observed at 6 and 12 months in individual studies.

conclusionPatients with advanced PD receiving LCIG showed significant sustained improvements in the burden of dyskinesia and non-motor symptoms up to 24 months after initiation.

Indexed as

DyskinesiasParkinson DiseaseAntiparkinson AgentsCarbidopaDrug CombinationsFollow-Up StudiesGelsHumansLevodopaQuality of LifeSleepAntiparkinson AgentsCarbidopaDrug CombinationsGelsLevodopacarbidopa/levodopameta-analysismotor symptomsParkinson’s diseasequality of life

Identifiers

PMID35964203
PMCPMC9661331
OpenAlexW4290830261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.